a For esophageal candidiasis, administer 50 mg IV daily (no 70-mg loading dose).
- No dosage adjustment is necessary for renal insufficiency, for mild hepatic insufficiency, or for the elderly; no supplementary doses are required after hemodialysis.
- Do not use diluents containing dextrose (α-D-glucose).
- CANCIDAS has not been adequately studied in patients younger than 18 years.
Dosage Adjustments
- For moderate hepatic insufficiency (Child-Pugh score 7–9), CANCIDAS 35 mg daily is recommended.
- Where recommended, a loading dose of 70 mg should still be administered.
- There is no clinical experience in patients with severe hepatic insufficiency (Child-Pugh score >9).
- Patients receiving rifampin should receive 70 mg of CANCIDAS daily. Patients receiving nevirapine, efavirenz, carbamazepine, dexamethasone, or phenytoin may require an increase in dose to 70 mg of CANCIDAS daily.
- CANCIDAS is contraindicated in patients with hypersensitivity to any component of this product.
- Concomitant use of CANCIDAS with cyclosporine should be limited to patients for whom the potential benefit outweighs the potential risk of increased hepatic enzyme abnormalities. See the Warning in the Prescribing Information.
- Laboratory abnormalities in liver function tests have been seen in healthy volunteers and patients treated with CANCIDAS. In some patients with serious underlying conditions who were receiving multiple concomitant medications along with CANCIDAS, clinical hepatic abnormalities have also occurred. Isolated cases of significant hepatic dysfunction, hepatitis, or worsening hepatic failure have been reported in patients; a causal relationship to CANCIDAS has not been established. Patients who develop abnormal liver function tests during therapy with CANCIDAS should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing therapy with CANCIDAS.
- For patients receiving CANCIDAS and tacrolimus, standard monitoring of tacrolimus blood concentrations and appropriate tacrolimus dosage adjustments are recommended.
- Possible histamine-mediated symptoms have been reported, including rash, facial swelling, pruritus, sensation of warmth, and bronchospasm. Anaphylaxis has been reported during administration of CANCIDAS.
Before prescribing CANCIDAS, please read the Prescribing Information.
